Skip to Content
Developmental Therapeutics Program (DTP)
Last Updated: 04/02/15

TPB Publications

1996 Publications

  1. Egorin, M.J., Sentz, D.L., Rosen, D.M., Ballesteros, M.F., Kearns, C.M., Callery, P.S., Eiseman, J.L., 1996. Cancer Chemother. Pharmacol., 39(1-2), 51-60.
  2. Eiseman, J.L., Yuan, Z.M., Eddington, N.D., Sentz, D.L., Callery, P.S., Egorin, M.J., 1996. Plasma Pharmacokinetics and Urinary Excretion of the Polyamine Analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 Mice, Cancer Chemother. Pharmacol., 38(1), 13-20.
  3. Kelloff, G.J., Crowell, J.A., Hawk, E.T., Steele, V.E., Lubet, R.A., Boone, C.W., Covey, J.M., Doody, L.A., Omenn, L.A., Greenwald, P., Hong, W.K., Parkinson, D.R., Bagheri, D., Baxter, G.T., Blunden, M., Doeltz, M.K., Eisenhauer, K.M., Johnson, K., Knapp, G.G., Longfellow, D.G., Malone, W.F., Nayfield, S.G., Seifried, H.E., Swall, L.M., and Sigman, C.C., 1996. Strategy and Planning for Chemopreventive Drug Development: Clinical Development Plans II. J. Cellular Biochem (supp.) 26: 54-71.
  4. Reid, J.M., Walker, D.L., Ames, M.M., 1996. Preclinical Pharmacology of Ecteinascidin 729, a Marine Natural Product with Potent Antitumor Activity, Cancer Chemother. Pharmacol., 38(4), 329-34.
  5. Sedlacek, H.H., J. Czech, R. Naik, G. Kaur, P. Worland, M. Losiewicz, B. Parker, B. Carlson, A. Smith, A. Senderowicz and E. Sausville, 1996. Flavopiridol (L86 8275; NSC 649890), a New Kinase Inhibitor for Tumor Therapy. International J. Oncol. 9: 1143-1168.
  6. Volpe, D.A., A. Garg, R.E. Parchment, K.P. Flora, J.E. Tomaszewski, M.J. Murphy, Jr. and C.K. Grieshaber, 1996. Myelotoxic Effects of the Bifunctional Alkylating Agent Bizelesin to Human, Canine and Murine Myeloid Progenitor Cells. Cancer Chemother. Pharmacol., 39, 143-149.

About the Branch Chief

For information regarding the TPB, please contact Dr. Jerry M. Collins, Associate Director, collinsje@mail.nih.gov